^Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, et al. (December 2009). "Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation". The Journal of Pharmacology and Experimental Therapeutics. 331 (3): 882–895.
doi:
10.1124/jpet.109.158329.
PMID19720877.
^Selness SR, Devraj RV, Devadas B, Walker JK, Boehm TL, Durley RC, et al. (July 2011). "Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase". Bioorganic & Medicinal Chemistry Letters. 21 (13): 4066–4071.
doi:
10.1016/j.bmcl.2011.04.121.
PMID21641211.
^MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF (August 2013). "Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial". Thorax. 68 (8): 738–745.
doi:
10.1136/thoraxjnl-2012-202744.
PMID23539534.
^Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, et al. (December 2009). "Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation". The Journal of Pharmacology and Experimental Therapeutics. 331 (3): 882–895.
doi:
10.1124/jpet.109.158329.
PMID19720877.
^Selness SR, Devraj RV, Devadas B, Walker JK, Boehm TL, Durley RC, et al. (July 2011). "Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase". Bioorganic & Medicinal Chemistry Letters. 21 (13): 4066–4071.
doi:
10.1016/j.bmcl.2011.04.121.
PMID21641211.
^MacNee W, Allan RJ, Jones I, De Salvo MC, Tan LF (August 2013). "Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial". Thorax. 68 (8): 738–745.
doi:
10.1136/thoraxjnl-2012-202744.
PMID23539534.